Page 51 - NATIONAL INSTITUTES OF HEALTH (NIH) GUIDELINES FOR CONDUCTING RESEARCH IN MINISTRY OF HEALTH (MOH) INSTITUTIONS & FACILITIES 3RD EDITION 2021
P. 51

34.   Diseases Control Division, Ministry of Health Malaysia. Garispanduan Pengimportan
                        dan Pengeksportan Tisu Manusia atau Mana-Mana Bahagiannya. Available at: http://
                        www.bless2.gov.my/wp-content/uploads/2020/10/CG-Permit-to-Import-or-Export-
                        of-Human-Tissues-or-Part-Thereof.pdf
                  35.   Laws of Malaysia, Act 678 - Biosafety Act 2007
                  36.   World Health Organization (2020) Laboratory Biosafety Manual 4  Edition.  https://
                                                                              th
                        www.who.int/publications/i/item/9789240011311 (Accessed on 22 November 2021)
                  37.   Intellectual  Property  Corporation  of  Malaysia  https://www.myipo.gov.my/en/home/
                        (Accessed on 26 July 2021).
                  38.   Institute for Medical Research (IMR), National Institutes of Health, Ministry of Health
                        Malaysia (2017), Understanding Intellectual Property Workshop.
                  39.   Management Services Division, Ministry of Health Malaysia (2019). Garis Panduan Me-
                        kanisme Pengkomersialan Produk Inovasi KKM 2019. Retrieved from https://penguru-
                        san.moh.gov.my/v3/download (Accessed on 16 July 2021).
                  40.   Malaysia Science and Technology Information Centre, Ministry of Science, Tech-
                        nology, and Innovation Malaysia https://mastic.mosti.gov.my/index.php/taxonomy/
                        term/47
                        (Accessed on 26 July 2021)
                  41.   Fund Division, Ministry of Science, Technology and Innovation (MOSTI). Garis Pan-
                        duan Dana Bridging (BGF) (2021). Available at  https://edana.mosti.gov.my/edana/
                        frontend/web/guidelines/garispanduanbgf17062021.pdf
                  42.   Fund Division, Ministry of Science, Technology and Innovation (MOSTI). Garis Pan-
                        duan Dana Pembangunan Teknologi 2 (TeD 2) (2021). Available at https://edana.mosti.
                        gov.my/edana/frontend/web/guidelines/garispanduanted217062021.pdf
                  43.   Ellenberg SS, Fleming TR, DeMets DL (2002). Data Monitoring Committees in Clinical
                        Trials: A Practical Perspective (Statistics In Practice) Chichester, England: John Wiley
                        & Sons, LTD.
                  44.   Ethical Issues during the Conduct of Clinical Trials. Proceedings of the American Tho-
                        racic Society. Silverman H. 2007;4(2):180-184. Available at https://www.atsjournals.
                        org/doi/full/10.1513/pats.200701-010GC
                  45.   Guidance for Clinical Trial Sponsors, Establishment and Operation of Clinical Trial Data
                        Monitoring Committees, U.S. Department of Health and Human Services, Food and
                        Drug Administration. (2006). Available at  https://www.fda.gov/media/75398/down-
                        load. (Accessed on 10 November 2021)
                  46.   National Science Council, Academy of Sciences Malaysia (2020). The Malaysian Code
                        of Responsible Conduct in Research 2nd Edition, published 19 March 2021.
























                                                  NIH Guidelines for Conducting Research in MOH, 2021  35
   46   47   48   49   50   51   52   53   54   55   56